Charles Schwab Investment Management Inc. Sells 7,214 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Supernus Pharmaceuticals by 1.0%, owning approximately $24.44 million worth of shares after selling 7,214 shares in the first quarter.
• CEO Jack A. Khattar sold 140,000 shares at an average price of $42.02, decreasing his ownership by nearly 12%, while insiders have sold a total of 152,826 shares in the last three months.
• Supernus Pharmaceuticals received an upgrade to a buy rating from Wall Street Zen, with a consensus rating of "Moderate Buy" and an average price target of $41.00.

Charles Schwab Investment Management Inc. lowered its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 1.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 746,149 shares of the specialty pharmaceutical company's stock after selling 7,214 shares during the period. Charles Schwab Investment Management Inc. owned about 1.33% of Supernus Pharmaceuticals worth $24,436,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in SUPN. LPL Financial LLC grew its stake in shares of Supernus Pharmaceuticals by 18.9% in the 4th quarter. LPL Financial LLC now owns 12,741 shares of the specialty pharmaceutical company's stock worth $461,000 after purchasing an additional 2,029 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Supernus Pharmaceuticals by 14.4% in the 4th quarter. Wells Fargo & Company MN now owns 63,237 shares of the specialty pharmaceutical company's stock worth $2,287,000 after purchasing an additional 7,961 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 6.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock worth $2,169,000 after purchasing an additional 3,495 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Supernus Pharmaceuticals by 6.6% in the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company's stock worth $275,000 after purchasing an additional 473 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $6,847,000.

Wall Street Analyst Weigh In

SUPN has been the subject of several recent analyst reports. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Finally, Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $41.00.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock traded up $1.56 during trading on Friday, hitting $44.88. 1,047,668 shares of the company were exchanged, compared to its average volume of 1,064,514. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of 39.03 and a beta of 0.74. The business's 50-day simple moving average is $35.41 and its 200 day simple moving average is $33.69. Supernus Pharmaceuticals, Inc. has a twelve month low of $29.16 and a twelve month high of $45.01.

Insider Buying and Selling

In related news, CEO Jack A. Khattar sold 140,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total transaction of $5,882,800.00. Following the transaction, the chief executive officer owned 1,030,183 shares of the company's stock, valued at approximately $43,288,289.66. This trade represents a 11.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bethany Sensenig sold 5,369 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total transaction of $226,840.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 152,826 shares of company stock worth $6,424,773. 8.80% of the stock is owned by company insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.